Dr. David Schubert to advise Nemus on neuroprotection and CNS applications of the company’s proprietary cannabinoid portfolio

COSTA MESA, CA. , March 21, 2018 (GLOBE NEWSWIRE) -- Nemus Bioscience, Inc. (OTCQB: NMUS), focused on the development of cannabinoid-based therapeutics to address global medical indications, especially those of unmet medical need, announced today that Professor David Schubert, Laboratory Head of the Salk Institute’s Cellular Neurobiology Laboratory, will join the Nemus Bioscience Scientific Advisory Board.

Dr. Schubert is a two-time recipient of the Jacob Javits Award for outstanding contributions to neuroscience from the National Institute of Neurological Disorders and Stroke (NINDS), a section of the National Institutes of Health (NIH). He has numerous published papers, most notably highlighting the potential value of natural products and their synthetic derivatives as “geroprotectors” in managing degenerative changes associated with senescence, including neuroprotection. Dr. Schubert’s work includes identifying the beneficial effects of tetrahydrocannabinol (THC) in removing amyloid-beta, a destructive protein associated with Alzheimer’s Disease.

“Dr. Schubert is a global expert in the science of cellular aging, particularly in the central nervous system (CNS) related to both endocannabinoids and those exogenously administered,” commented Brian Murphy, M.D., CEO and Chief Medical officer of Nemus. “We are delighted to welcome Dr. Schubert to the Nemus team and look forward to his input as we advance our pipeline.”

“Nemus has unique, bio-engineered cannabinoids, chemically designed to cross physiological membranes, especially the blood-brain barrier,” noted Dr. Schubert. “This molecular versatility could present unique opportunities to address a variety of human conditions associated with aging and associated disease-related debilitating effects on the nervous system. I look forward to advising the Nemus team on paths forward to assess the benefits of their library of potential cannabinoid-based medicines.”

Nemus is advancing its prodrug NB1111 for glaucoma through preclinical work, and aims to move the drug from formulation stage to a first-in-human study by early 2019. The company is also working to complete synthesis scale-up for its proprietary CBD analogue this year.

ABOUT NEMUS BIOSCIENCE, INC.

The Company is a biopharmaceutical company, headquartered in Costa Mesa, California, focused on the discovery, development, and commercialization of cannabinoid-based therapeutics for significant unmet medical needs in global markets. Utilizing certain proprietary technology licensed from the University of Mississippi, NEMUS is working to develop novel ways to deliver cannabinoid-based drugs for specific indications, with the aim of optimizing the clinical effects of such drugs, while limiting potential adverse events. NEMUS's strategy is to explore the use of natural and synthetic compounds, alone or in combination with partners. The Company is led by a highly qualified team of executives with decades of biopharmaceutical experience and significant background in early-stage drug development.

For more information, visit www.nemusbioscience.com .

FORWARD LOOKING STATEMENTS

This press release contains forward-looking statements, including statements about the studies relating to and the potential benefits of NEMUS’ proprietary, cannabinoid-based therapeutics, product testing and development timetable and potential partnerships. Such statements and other statements in this press release that are not descriptions of historical facts are forward-looking statements that are based on management's current expectations and assumptions and are subject to risks and uncertainties. If such risks or uncertainties materialize or such assumptions prove incorrect, our business, operating results, financial condition and stock price could be materially negatively affected. In some cases, forward-looking statements can be identified by terminology including "goal," "focus," "aims," “expects,” “plans,” "believes," "can," “could,” "challenge," "predictable," "will," or the negative of these terms or other comparable terminology. We operate in a rapidly changing environment and new risks emerge from time to time. As a result, it is not possible for our management to predict all risks, nor can we assess the impact of all factors on our business or the extent to which any factor, or combination of factors, may cause actual results to differ materially from those contained in any forward-looking statements the Company may make. Risks and uncertainties that may cause actual results to differ materially include, among others, our capital resources, uncertainty regarding the results of future testing and development efforts and other risks that are described in the Risk Factors section of NEMUS’s most recent annual or quarterly report filed with the Securities and Exchange Commission. Except as expressly required by law, NEMUS disclaims any intent or obligation to update these forward-looking statements.

CONTACT: NEMUS Investor Relations PCG Advisory Group Adam Holdsworth Email: adamh@pcgadvisory.com Phone: 646-862-4607